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Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs) have been widely used and are a major therapeutic advance in
psychopharmacology. However, their pharmacology is quite heterogeneous. The SSRI fluvoxamine, with sigma-1 receptor
agonism, is shown to potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC 12 cells. However, the precise
cellular and molecular mechanisms underlying potentiation by fluvoxamine are not fully understood. In this study, we
examined the roles of cellular signaling pathways in the potentiation of NGF-induced neurite outgrowth by fluvoxamine
and sigma-1 receptor agonists.
Methods and Findings: The effects of three SSRIs (fluvoxamine, sertraline, paroxetine) and three sigma-1 receptor agonists
(SA4503, 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), and dehydroepiandrosterone (DHEA)-sulfate) on NGF-induced neurite
outgrowth in PC12 cells were examined. Also examined were the effects of the sigma-1 receptor antagonist NE-100, inositol
1,4,5-triphosphate (IP3) receptor antagonist, and specific inhibitors of signaling pathways in the potentiation of NGF-induced
neurite outgrowth by selective sigma-1 receptor agonist SA4503. Fluvoxamine (but not sertraline or paroxetine) and the sigma-
1 receptor agonists SA4503, PPBP, and DHEA-sulfate significantly potentiated NGF-induced neurite outgrowth in PC12 cells in a
concentration-dependent manner. The potentiation by fluvoxamine and the three sigma-1 receptor agonists was blocked by
co-administration ofthe selectivesigma-1 receptorantagonistNE-100, suggesting thatsigma-1receptorsplayarole inblocking
the enhancement of NGF-induced neurite outgrowth. Moreover, the potentiation by SA4503 was blocked by co-administration
of the IP3 receptor antagonist xestospongin C. In addition, the specific inhibitors of phospholipase C (PLC-c),
phosphatidylinositol 3-kinase (PI3K), p38MAPK, c-Jun N-terminal kinase (JNK), and the Ras/Raf/mitogen-activated protein
kinase (MAPK) signaling pathways blocked the potentiation of NGF-induced neurite outgrowth by SA4503.
Conclusion: These findings suggest that stimulation of sigma-1 receptors and subsequent interaction with IP3 receptors,
PLC-c, PI3K, p38MAPK, JNK, and the Ras/Raf/MAPK signaling pathways are involved in the mechanisms of action of sigma-1
receptor agonists such as fluvoxamine and SA4503.
Citation: Nishimura T, Ishima T, Iyo M, Hashimoto K (2008) Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1
Receptors, IP3 Receptors and Cellular Signaling Pathways. PLoS ONE 3(7): e2558. doi:10.1371/journal.pone.0002558
Editor: Bernhard Baune, James Cook University, Australia
Received April 24, 2008; Accepted May 24, 2008; Published July 2, 2008
Copyright:  2008 Nishimura et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was partly supported by a grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to K.H.); this funding had
no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for
publication.
Competing Interests: Dr. Kenji Hashimoto reports receiving the speaker fees from Solvay, Meiji Seika, Asteras, Eli Lilly, Janssen, Pfizer, and Otsuka. Dr. Masaomi
Iyo reports receiving the speaker fees from Janssen, Meiji Seika., Dainippon-Sumitomo, GlaxoSmithKline, Novartis, Eli Lilly, Pfizer, and Otsuka. Ms. Tomoko
Nishimura and Ms. Tamaki Ishima report no competing interests.
* E-mail: hashimoto@faculty.chiba-u.jp
Introduction
Selective serotonin (5-HT; 5-hydroxytryptamine) reuptake
inhibitors (SSRIs) have emerged as a major therapeutic advance
in psychopharmacology. SSRIs are the treatment of choice for
many indications, including major depressive disorder, dysthymia,
panic disorder, obsessive-compulsive disorder, eating disorders,
and premenstrual dysphoric disorder. In contrast, it is well known
that their pharmacology is quite heterogeneous, although all of
them block 5-HT transporters, thus increasing 5-HT levels
throughout the central nervous system (CNS) [1–9].
Accumulating evidence suggests that sigma-1 receptors, which
are intracellular endoplasmic reticulum (ER) proteins, are involved
in both the neuroplasticity and pathophysiology of neuropsychi-
atric diseases such as major depressive disorder, anxiety,
schizophrenia, and Alzheimer’s disease [10–18]. Previously, we
reported that some SSRIs possess high to moderate affinities for
sigma-1 receptors in the rat brain. The rank order of SSRIs
affinities for sigma-1 receptors is fluvoxamine (Ki=36 nM).ser-
traline (Ki=57 nM)..paroxetine (Ki=1893 nM) [19]. Recent-
ly, we reported that fluvoxamine, but not paroxetine, significantly
ameliorated cognitive deficits in mice after repeated phencyclidine
administration, and that the effects of fluvoxamine were
antagonized by co-administration of the selective sigma-1 receptor
antagonist NE-100 [20], suggesting that sigma-1 receptors are
involved in the mechanism of action of fluvoxamine [9]. Interest-
PLoS ONE | www.plosone.org 1 July 2008 | Volume 3 | Issue 7 | e2558ingly, it has been demonstrated that sigma-1 receptor agonists
including fluvoxamine could potentiate nerve growth factor (NGF)-
induced neurite outgrowth in PC12 cells, and that NE-100 blocked
the potentiation by sigma-1 receptor agonists, suggesting sigma-1
receptors are involved in neuroplasticity [21]. However, the precise
cellular mechanismsunderlyingthe potentiation bysigma-1receptor
agonists are not fully understood [13,21].
It is therefore of great interest to study the precise cellular
mechanisms underlying the enhancement by fluvoxamine on
NGF-induced neurite sprouting in PC12 cells. In the present
study, we examined the effects of three SSRIs (fluvoxamine,
sertraline, paroxetine), as well as the effects of a sigma-1 receptor
agonist (4-phenyl-1-(4-phenylbutyl) piperidine (PPBP), dehydroepi-
androsterone-sulphate (DHEA)-sulfate) [9,22–28] and the selective
sigma-1 receptor agonist SA4503 [29,30], on NGF-induced neurite
outgrowth in PC12 cells. Furthermore, it is also known that sigma-1
receptors have been shown to interact with IP3 receptors (17,18).
Therefore, we examined the effects of NE-100 and xestospongin C
(a selective inositol 1,4,5-triphosphate (IP3) receptor antagonist) [31]
in order to investigate the roles of sigma-1 receptors and IP3
receptors in the mechanisms underlying the enhancement of NGF-
Figure 1. Effects of NGF on neurite outgrowth in PC12 cells.
Incubation of NGF (0, 2.5, 5.0, 10.0, 20.0 or 40.0 ng/ml) caused neurite
outgrowth in PC12 cells in a concentration dependent manner. The data
were shown as percentage of the number of cells with neurite outgrowth
in the number of total cells. The data show the mean6S.E.M (n=8).
doi:10.1371/journal.pone.0002558.g001
Figure 2. Effects of three SSRIs (fluvoxamine, sertraline, paroxetine) on NGF-induced neurite outgrowth in PC12 cells. Fluvoxamine
(The data show the mean6S.E.M (n=6)), paroxetine (The data show the mean6S.E.M (n=6)), sertraline (The data show the mean6S.E.M (n=6)).
Fluvoxamine (but not sertraline or paroxetine) significantly potentiated NGF-induced neurite outgrowth in PC12 cells in a concentration-dependent
manner. The potentiation by fluvoxamine was blocked by co-administration of the selective sigma-1 receptor antagonist NE-100 (1.0 mM). Number is
the concentration (mM) of drugs. *P,0.05, ***P,0.001 as compared with control (NGF alone group).
+++P,0.001 as compared with fluvoxamine
(10.0 mM) plus NE-100 group.
doi:10.1371/journal.pone.0002558.g002
Sigma-1 Receptors and Neurite
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effectsofspecificinhibitors ofseveralcellularsignaling targets onthe
enhancement of NGF-induced neurite outgrowth by SA4503, since
several signal transduction molecules have been implicated in NGF-
induced neurite outgrowth [32].
Materials and Methods
Drugs
The drugs were obtained from the following sources: fluvox-
amine maleate (Solvay Seiyaku K.K., Tokyo, Japan); paroxetine
hydrochloride, dehydroepiandosterone-sulfate (DHEA-sulfate),
LY294002 (Sigma-Aldrich, St Louis, MO, USA); sertraline
(Toronto Research Chemicals Inc., North York, ON, Canada);
SA4503 (M’s Science Corporation, Kobe, Japan); NGF (Promega,
Madison, WI); xestospongin C, lovastatin, PD98059, GW5074,
SB203580, MEK 1/2 inhibitor (SL327), and SP600125 (Calbio-
chem-Novabiochem, San Diego, CA). The selective sigma-1
receptor antagonists NE-100 and 4-phenyl-1-(4-phenylbutyl)
piperidine (PPBP) were synthesized in our laboratory. Other
drugs were purchased from commercial sources.
Cell culture
PC12 sells (RIKEN Cell Bank, Tsukuba, Japan) were cultured at
37uC, 5%CO2 with Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 5% heat-inactivated fetal bovine serum (FBS),
10% heat-inactivated horse serum, and 1% penicillin. The medium
was changed two or three times a week. PC12 cells were plated onto
24-well tissue culture plates coated with poly-D-lysine/laminin.
Cells were plated at relatively low density (0.25610
4 cells/cm
2)i n
DMEM medium containing0.5%FBS, 1% penicillin streptomycin.
Medium containing a minimal level of serum (0.5% FBS) was used,
since serum is known to contain steroid hormones that bind to
sigma-1 receptors [21]. First, we examined the optimal concentra-
tion of NGF for NGF-induced neurite outgrowth in PC12 cells.
NGF (2.5, 5, 10, 20, 40 ng/ml) increased the number of cells with
neurite outgrowth in PC12 cells in a concentration-dependent
manner (Figure 1). In the subsequent studies, 2.5 ng/ml of NGF
was used to study the potentiating effects of sigma-1 receptor
agonists on NGF-induced neurite outgrowth. Twenty-four hours
after plating, the medium was replaced with DMEM medium
containing 0.5% FBS and 1% penicillin streptomycin with NGF
(2.5 ng/ml) with or without several drugs.
Figure 3. Effects of three sigma-1 receptor agonists (SA4503, PPBP, DHEA-sulfate) on NGF-induced neurite outgrowth in PC12 cells.
SA4503 (The data show the mean6S.E.M (n=5–15)), PPBP (The data show the mean6S.E.M (n=8)), DHEA-sulfate (The data show the mean6S.E.M
(n=8)). These drugs (0.1, 1.0 or 10.0 mM) significantly potentiated NGF-induced neurite outgrowth in PC12 cells in a concentration-dependent
manner. The potentiation by these drugs was significantly blocked by co-administration of the selective sigma-1 receptor antagonist NE-100 (1.0 mM).
Number is the concentration (mM) of drugs. *P,0.05, **P,0.01, ***P,0.001 as compared with control (NGF alone group).
+++P,0.001 as compared
with drugs (10 mM) plus NE-100 group.
doi:10.1371/journal.pone.0002558.g003
Sigma-1 Receptors and Neurite
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Five days after incubation with NGF (2.5 ng/ml) with or
without the several drugs, morphometric analysis was performed
on digitized images of live cells taken under phase-contrast
illumination with an inverted microscope linked to a camera.
Images of three fields per well were taken, with an average of
100 cells per field. Differentiated cells were counted by visual
examination of the field; only cells that had at least one neurite
with a length equal to the cell body diameter were counted, and
were then expressed as a percentage of the total cells in the field.
The counting was performed in a blinded manner.
Immunocytochemistry
Cells were fixed for 30 min at room temperature with 4%
paraformaldehyde then permeabilized with 0.2% Triton and
blocked with 1.5% normal goat serum, 0.1% bovine serum
albumin (BSA) in 0.1 M phosphate-buffer saline for 1 h to reduce
nonspecific binding. Cells were incubated overnight at 4uC with
anti-microtubule-associated protein 2 (MAP-2) antibodies (1:1000
dilution in blocking solution, Chemicon International, Temecula,
CA, USA). The immunolabeling was visualized with secondary
antibodies conjugated to Alexa-488 (1:1000; Invitrogen, Carlsbad,
CA, USA). MAP-2 immuncytochemistry was visualized with a
fluorescence microscope (Axiovert 200, Carl Zeiss, Oberkocken,
Germany).
Statistical analysis
Data are expressed as means6S.E.M. Statistical analysis was
performed by using one-way analysis of variance (ANOVA) and
the post hoc Bonferroni/Dunn test. P values less than 0.05 were
considered statistically significant.
Results
Effects of SSRIs on NGF-induced neurite outgrowth
Fluvoxamine (0.1, 1.0, or 10 mM) significantly increased the
number of cells with neurite outgrowth by NGF (2.5 ng/ml) in
PC12 cells, in a concentration-dependent manner (Figure 2 and
Figure 4. Representative photographs of MAP-2 immunocytochemistry in PC12 cells. (A) Control (NGF (2.5 ng/ml) alone) (B) NGF+SA4503
(1.0 mM), (C) NGF+SA4503 (1.0 mM)/NE-100 (1.0 mM), (D) NGF+Fluvoxamine (10.0 mM), (E) NGF+Fluvoxamine (10.0 mM)/NE-100 (1.0 mM), (F) NE-100
(1.0 mM). Incubation of SA4503 (1.0 mM) or fluvoxamine (10 mM) potentiated NGF-induced neurite outgrowth in PC12 cells. The potentiating effects
of SA4503 or fluvoxamine on the NGF-induced neurite outgrowth were antagonized by co-administration of NE-100 (1.0 mM). Furthermore, NE-100
(1.0 mM) alone did not alter NGF-induced neurite outgrowth.
doi:10.1371/journal.pone.0002558.g004
Figure 5. Effects of the IP3 receptor antagonist xestospongin C
on potentiation of NGF-induced neurite outgrowth by SA4503.
The potentiating effects of SA4503 (1.0 mM) on the NGF-induced
neurite outgrowth were antagonized by co-administration of xestos-
pongin C (1.0 mM). Furthermore, xestospongin C (1.0 mM) alone did not
alter NGF-induced neurite outgrowth. The data show the mean6SEM
(n=12). ***p,0.001.
doi:10.1371/journal.pone.0002558.g005
Sigma-1 Receptors and Neurite
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1.0, or 10 mM) did not increase the number of cells with neurite
outgrowth by NGF (2.5 ng/ml). A higher concentration (10 mM)
of paroxetine and sertraline significantly decreased the number of
cells with NGF-induced neurite outgrowth, suggesting the cellular
toxicity of these drugs in PC12 cells (Figure 2).
Role of sigma-1 receptors in the potentiation of NGF-
induced neurite outgrowth by fluvoxamine and SA4503
The selective and potent sigma-1 receptor agonist SA4503 (0.01,
0.1, or 1.0 mM) significantly increased the number of cells with
neurite outgrowth by NGF (2.5 ng/ml) in PC12 cells, in a
concentration-dependent manner (Figure 3 and 4). In addition,
other sigma-1 receptor agonists–PPBP (0.1, 1.0, or 10 mM) [22–26]
and DHEA-sulphate (0.1, 1.0, or 10 mM) [9,27,28]–significantly
increased the number of such cells, also in a concentration-
dependent manner (Figure 3). In the absence of NGF, sigma-1
receptor agonists did not produce neurite outgrowth in PC12 cells
(data not shown).
To investigate the role of sigma-1 receptors, we examined the
effects of NE-100 (a selective sigma-1 receptor antagonist) on the
potentiation of NGF-induced neurite outgrowth by fluvoxamine,
SA4503, PPBP, and DHEA-sulphate. Co-administration of NE-
100 (1.0 mM) significantly blocked such potentiation by fluvox-
amine (10 mM), SA4503 (1.0 mM), PPBP (10 mM), or DHEA-
sulphate (10 mM) (Figure 2 and 3). Furthermore, administration
of NE-100 (1.0 mM) alone did not alter NGF-induced neurite
outgrowth in PC12 cells (Figure 2).
Role of IP3 receptors in the potentiation of NGF-induced
neurite outgrowth by SA4503
Sigma-1 receptors have been shown to interact with IP3
receptors (17,18,33–35). To investigate the role of IP3 receptors
in the effects of SA4503 on NGF-induced neurite outgrowth, we
examined the effects of xestospongin C (a selective, reversible, and
membrane-permeable inhibitor of IP3 receptors) [31] on the
effects of SA4503 on NGF-induced neurite outgrowth. Co-
administration of xestospongin C (1.0 mM) significantly blocked
the potentiation of NGF-induced neurite outgrowth by SA4503
(1.0 mM) (Figure 5). Furthermore, administration of xestospongin
C (1.0 mM) alone did not alter NGF-induced neurite outgrowth in
PC12 cells (Figure 5).
Figure 6. Effects of the specific inhibitors of PLC-c, PI3K, p38MAPK, and JNK on potentiation of NGF-induced neurite outgrowth by
SA4503. The potentiating effects of SA4503 (1.0 mM) on the NGF-induced neurite outgrowth were antagonized by co-administration of the PLC-c
inhibitor (U73122; 1.0 mM), the PI3K inhibitor (LY294002; 1.0 mM), the p38MAPK inhibitor (SB203580; 1.0 mM), and the JNK inhibitor (SP600125;
1.0 mM). The data show the mean6SEM (n=4–12). ***p,0.001.
doi:10.1371/journal.pone.0002558.g006
Sigma-1 Receptors and Neurite
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potentiation of NGF-induced neurite outgrowth by
SA4503
Next, we examined the effects of the specific inhibitors of PLC-
c, PI3K, p38 MAPK, and c-Jun N-terminal kinase (JNK), since
these signaling molecules are activated upon the addition of NGF
[36]. The PLC-c inhibitor (U73122; 1.0 mM), PI3K inhibitor
(LY294002; 1.0 mM), p38 MAPK inhibitor (SB203580; 1.0 mM),
and JNK inhibitor (SP600125; 1.0 mM) significantly blocked the
potentiation of NGF-induced neurite outgrowth by SA4503
(1.0 mM) (Figure 6). In contrast, these inhibitors alone did not
alter NGF-induced neurite outgrowth in PC12 cells (Figure 6).
Role of Raf/Ras/ERK/MAPK pathway in the potentiation
of NGF-induced neurite outgrowth by SA4503
The Raf/Ras/ERK/MAPK pathway is known to be involved
in NGF-induced outgrowth [32]. Therefore, we examined the
effects of this pathway’s specific inhibitors. The Ras inhibitor
(GW5074; 1.0 mM), Raf inhibitor (lovastatin; 1.0 mM), MEK1/2
inhibitor (SL327; 1.0 mM), and MAPK inhibitor (PD98059;
1.0 mM) significantly blocked the potentiation of NGF-induced
neurite outgrowth by SA4503 (1.0 mM) (Figure 7). In contrast,
these inhibitors alone did not alter NGF-induced neurite
outgrowth in PC12 cells (Figure 7).
Discussion
In the present study, we found that fluvoxamine (but not
sertraline or paroxetine) and the sigma-1 receptor agonists
(SA4503, PPBP, DHEA-sulfate) could potentiate NGF-induced
neurite outgrowth in PC12 cells, and that the effects of these drugs
were blocked by co-incubation with the selective sigma-1 receptor
antagonist NE-100. These findings suggest that agonism at sigma-
1 receptors for these drugs is involved in the mechanisms
underlying the drugs’ potentiation of NGF-induced neurite
outgrowth.
As shown in Figure 1, NGF increased the number of cells with
neurite outgrowth in PC12, in a concentration dependent manner.
To examine whether or not the NGF levels are altered by
incubation with sigma-1 receptor agonists, we measured the levels
of NGF in PC12 cells with or without sigma-1 receptor agonist
SA4503. No differences of NGF levels were shown in the between
control group and SA4503-treated group (data not shown). It is,
therefore, unlikely that the potentaition of NGF-induced neurite
outgrowth by sigma-1 receptor agonists might be due to increased
levels of NGF.
Unlike fluvoxamine, sertraline, which has a moderate affinity
for sigma-1 receptors, did not alter NGF-induced neurite
outgrowth. The reasons underlying this discrepancy between
these two SSRIs are currently unclear. One possibility may involve
Figure 7. Effects of the specific inhibitors of Ras, Raf, MEK1/2, and MAPK on potentiation of NGF-induced neurite outgrowth by
SA4503. The potentiating effects of SA4503 (1.0 mM) on the NGF-induced neurite outgrowth were antagonized by co-administration of the Ras
inhibitor (GW5074; 1.0 mM), the Raf inhibitor (lovastatin; 1.0 mM), the MEK1/2 inhibitor (MEK1/2 inhibitor; 1.0 mM), and the MAPK inhibitor (PD98059;
1.0 mM). The data show the mean6SEM (n=4 or 8). *P,0.05, ***p,0.001.
doi:10.1371/journal.pone.0002558.g007
Sigma-1 Receptors and Neurite
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between these SSRIs at sigma-1 receptors. Interestingly, we
recently found that, in a novel object recognition test, phencycli-
dine-induced cognitive deficits could be significantly improved by
subsequent subchronic (14 days) administration of fluvoxamine,
but not of sertraline, suggesting that sigma-1 receptor agonism is
involved in fluvoxamine’s mechanism of action [9], Ishima et al.,
submitted. Taken together, these findings suggest that fluvoxamine
and sertraline may function as an agonist and an antagonist at
sigma-1 receptors, respectively, although further study is neces-
sary. Another possibility may be that other pharmacological
activities of sertraline mask the effects of sigma-1 receptor
agonism. In this study, we also found that high concentration
(10 mM) of paroxetine and sertraline, but not fluvoxamine, showed
cytotoxicity in PC12 cells, suggesting that fluvoxamine may be a
safe drug than paroxetine and sertraline.
Sigma-1 receptors have been shown to affect intracellular Ca
2+
signaling, although the precise molecular and cellular mechanisms
underlying this effect are unknown. Sigma-1 receptors bind to IP3
receptors in ER, and sigma-1 receptors regulate Ca
2+ release from
intracellular Ca
2+ storage sites [12]. Very recently, Hayashi and
Su [17] reported that sigma-1 receptors function as novel ligand-
operated chaperones that specifically target mitochondrion-
associated ER membrane. Furthermore, sigma-1 receptors form
Ca
2+-sensitive chaperone machinery with another chaperone, BiP,
and prolong Ca
2+ signaling from ER into mitochondria by
stabilizing IP3 receptors at mitochondrion-associated ER mem-
brane [17]. In this study, we found that the IP3 receptor antagonist
xestospongin C significantly blocked the potentiation of NGF-
induced neurite outgrowth by SA4503, suggesting the role of IP3
receptors on sigma-1 receptor-mediated potentiation of NGF-
induced neurite outgrowth. Therefore, it is likely that stimulation
at sigma-1 receptors by sigma-1 receptor agonists and subsequent
interaction with IP3 receptors are involved in the mechanism
underlying the potentiation of NGF-induced neurite outgrowth by
sigma-1 receptor agonists.
NGF binds to the high-affinity tyrosine receptor TrkA, initiating
several signaling pathways affecting both morphological and
Figure 8. Proposed mechanism for potentiation of NGF-induced neurite outgrowth by sigma-1 receptor agonists. NGF binding to cell-
surface TrkA receptor results in activated receptor complexes, which contain adaptors such as SHC (SH2-containing protein), GRB2 (growth-factor-
receptor bound protein 2) and Gab (GRB2-associated binding) proteins. These proteins recruit the protein SOS, increasing Ras-guanosine
triphosphate (Ras-GTP) levels by catalyzing nucleotide exchange on Ras. Ras also activates the PI3K-PDK1 (3-phosphoinosisitide-dependent protein
kinase 1)- Akt pathway. The activation of TrkA by NGF leads to activation of multiple signaling pathways, including PLC-c, PI3K, p38MAPK, and JNK
signaling pathways and Ras/Raf/MEK/ERK/MAPK pathways. The activation of sigma-1 receptors on the endoplasmic reticulum (ER) by sigma-1
receptor agonists (e.g., SA4503 and fluvoxamine) might interact with IP3 receptors on the ER. Ca
2+ released by the interaction between sigma-1
receptors and IP3 receptors may play a role in the potentiation of NGF-induced neurite outgrowth in PC12 cells. Subsequently, several signaling
pathways are implicated in the potentiation of NGF-induced neurite outgrowth by sigma-1 receptor agonists.
doi:10.1371/journal.pone.0002558.g008
Sigma-1 Receptors and Neurite
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including PLC-c, PI3K, p38 MAPK, and JNK, are activated
upon the addition of NGF [38]. PLC-c catalyzes the hydrolysis of
phosphatidylinositol-4,5-bisphosphate (PIP2) to diacylglycerol
(DAG) and inositol triphosphate (IP3). DAG activates protein
kinase C, and IP3 promotes transient release of Ca
2+ from the ER
[39]. The pathway via PLC-c is responsible for NGF-induced cell
differentiation [40] and neurite outgrowth [41]. Furthermore,
stimulation of PI3K is reported to be involved in the promotion of
neurite outgrowth in PC12 cells [42]. In this study, we found that
the PLC-c inhibitor U73122 and the PI3K inhibitor LY294002
significantly blocked the potentiation of NGF-induced neurite
outgrowth by SA4503. Moreover, we found that both the
p38MAPK inhibitor SB203580 and the JNK inhibitor
SP600125 significantly blocked the potentiation of NGF-induced
neurite outgrowth by SA4503. In addition, it is also interesting that
neurite outgrowth induced by low concentration (2.5 ng/ml) of
NGF was not blocked by these inihibitors, consistent with a
previous report [43,44], suggesting the existence of novel
pathway(s) for NGF-induced neurite outgrowth. These findings
suggest that the PLC-c, PI3K, p38MAPK, and JNK signaling
pathways are involved in the potentiation of NGF-induced neurite
outgrowth by sigma-1 receptor agonists (Figure 8). In addition,
we found that the specific inhibitors for the Raf/Ras/MEK/
MAPK pathways significantly blocked the potentiation of NGF-
induced neurite outgrowth by SA4503, suggesting that these
pathways are involved in the potentiation of NGF-induced neurite
outgrowth by sigma-1 receptor agonists (Figure 8).
Our recent positron emission tomography (PET) study demon-
strated that, after a single oral administration, fluvoxamine bound
to sigma-1 receptors in the living human brain [45]. This finding
suggests that sigma-1 receptors are involved in the mechanism of
action of fluvoxamine in the human brain [45]. Taken together,
the past and present findings suggest that, unlike paroxetine and
sertraline, the SSRI fluvoxamine, with its sigma-1 receptor
agonistic activity, might be a unique therapeutic drug for
neuropsychiatric diseases.
In conclusion, the present results suggest that, as a sigma-1
receptor agonist, fluvoxamine could potentiate the NGF-induced
neurite outgrowth in PC12 cells. Furthermore, it is likely that
interaction with IP3 receptors and several subsequent signaling
molecules are involved in the mechanism underlying the
pharmacological action of sigma-1 receptor agonists. Therefore,
it is likely that sigma-1 receptor agonists such as fluvoxamine and
DHEA-sulfate, which are available around the world, would be
unique therapeutic drugs for neuropsychiatric diseases.
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